The Clinical Utility of DCISionRT® on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery

• DOI: 10.1245/s10434-021-09903-1
• Publication Date: 2021-04-05T19:02:45Z
• Authors: Chirag Shah; Troy Bremer; Charles Cox; Pat Whitworth; Rakesh Patel; Anushka Patel; Eric Brown; Linsey Gold; David Rock; Lee Riley; Christy Kesslering; Sheree Brown; Robert Gabordi; James Pellicane; Rachel Rabinovich; Sadia Khan; Sandra Templeton; Lonika Majithia; Shawna C. Willey; Fredrik Wärnberg; Naamit K. Gerber; Steve Shivers; Frank A. Vicini
• Keywords: Surgical oncology; Breast-conserving surgery

The role of radiation therapy (RT) following breast-conserving surgery (BCS) in ductal carcinoma situ (DCIS) remains controversial. Trials have not identified a low-risk cohort, based on clinicopathologic features, who do benefit from RT. A biosignature (DCISionRT®) that evaluates recurrence risk has been developed and validated. We evaluated the impact DCISionRT clinicians' recommendations for adjuvant RT.The PREDICT study is prospective, multi-institutional, observational registry which patients underwent testing. primary endpoint was to identify percentage where testing led change RT recommendations.Overall, 539 women were included this study. Pre testing, recommended 69% patients; however, post-testing, recommendation made 42% compared with pre-testing recommendation; decreased by 20%. For initially receive an pre-test, 35% had their changed add while post-test, 46% omit after initial When considered conjunction other factors, elevated score group (DS > 3) strongest association (odds ratio 43.4) age, grade, size, margin status, factors.DCISionRT provided information significantly or Compared traditional features used determine against RT, factor most strongly associated result, factors importance being patient preference, tumor grade.